Decentralised Clinical Trials - How Place Affects Data
Decentralised clinical trials, a potential solution for the complexity of rare disease clinical trials, but what impact may place have?
Decentralised Clinical Trials - How Place Affects Data
SPIN ‘at Work’ in Scientific, Patient and Policy Conferences in Canada
Book: From Big Pharma to Commons
HTA: From Neoliberal Technocracy to Sustainable Democracy?
Solidarity in Crowdfunding for Rare Disease Treatment
First Allogenic CAR-T Treatment One Step Closer to Market Authorisation
Ultra-Rare Diseases and the Need to Invent a New Business Model
Scientific Colonialism in Rare Diseases: New Ethical Guidelines
Genomic Surveillance: The Key to Canada’s Public Health?
Framing the Wicked Problem of Orphan Drugs
From diagnosis to novel gene therapy treatment in three years: Proof of alternative forms
SPINRAZA Granted A Negative Reimbursement for Canadians with Spinal Muscular Atrophy
The Dutch Orphan Drug Access Protocol
Preparing the Future of Therapeutic and Social Innovation: The Initiative of Patient Organizations
Public-private partnerships and pharmaceutical social innovation in Brazil
Cells Causing Tumours in Tuberous Sclerosis Complex: A Medical Mystery Solved
About Cooperation and Clusterization Involved in the Development of Rare Disease Drugs
Focusing on Patient Stories
From Studying to Intervening: Advancing Social Pharmaceutical Innovation
What Counts In Pricing Drugs?